An Integrated BioSci Investing Alpha-Intelligence: How To Best Allocate Your Capital In The IBI Long-Term Portfolio?

Summary

• IBI Long-Term portfolio is compounding over 27% as of Jan. 12, 2018. New portfolio additions are continuing to deliver substantial profits.
• Notable performers continued to add further values. For those biosciences, it’s not a bad idea to take 25% profits while keeping the rest for the long haul.
• Despite that the best strategy is to mirror IBI long-term portfolio, there are alternative approaches to capture the lucrative profits in bioscience.
• We’ll share with readers our exchange with Len Nguyen (a highly insightful partner of our expert community).
• This is the Alpha-Intelligence for next week that we wish to publish in advanced for subscribers.

“Successful investing takes time, discipline and patience. No matter how great the talent or effort, some things just take time: You can't produce a baby in one month by getting nine women pregnant.” - The Oracle of Omaha (Warren Buffett)

Since Integrated BioSci Investing (“IBI”) commenced operation back on June 27, 2017, we’ve compounded the 27% composite gains for the IBI Long-Term portfolio. Our robust growth is mostly due to the notable performers as depicted in table 1. Accordingly, our picks in Kite Pharma (NASDAQ:KITE), Nektar Therapeutics (NASDAQ:NKTR), Spectrum Pharmaceuticals (NASDAQ:SPPI), Atara Biotherapeutics (NASDAQ:ATRA), Amicus Therapeutics (NASDAQ:FOLD), Exelixis Inc (NASDAQ:EXEL), and Crispr Therapeutics (NASDAQ:CRSP) procured 82%, 282%, 153%, 100%, 62%, 59%, and 45%, respectively.

Figure 1: Notable IBI performers. (Source: Google Finance).

Without further introduction, we’ll share with you the exchange between Dr. Tran BioSci of Integrated BioSci Investing with Len Nguyen (that can shed further insight into how to best use the IBI Long-Term Portfolio).

LN: What do you recommend as the percentage of a particular stock in the IBI portfolio that one should allocate?

Dr. Tran: I suggest that investors allocate an equal percentage to all bioscience in the IBI Long-Term portfolio. Notwithstanding, for certain equities that have compelling reasons with nearly 100% certainty that they can trump other issues, I'd double up the stakes (but no more than that). Notably, there are always the random chances that no matter how strong a thesis is, it will not be played out as one anticipated; hence, it’s best to exercise adequate diversification to minimize the risks while maximizing one’s chances to find the multi-bagger rewards.

You can access the in-depth Integrated BioSci Investing research through our Integrated BioSci Investing marketplace.

Author’s Notes: We’re honored that you took the time out of your busy day to read our market intelligence. Founded by Dr. Hung Tran, MD, MS, CNPR, (in collaborations with Dr. Tran BioSci analyst, Ngoc Vu, and other PhDs), Integrated BioSci Investing (“IBI”) marketplace research is delivering stellar returns since inceptions. To name a few, Nektar Therapeutics (NASDAQ:NKTR) procured more than 210% profits; Spectrum Pharmaceuticals (NASDAQ:SPPI) delivered over 180% gains; Kite Pharma netted 82%. Exelixis Inc (NASDAQ:EXEL) earned greater than 50% capital appreciation. Our secret sauce is extreme due diligence coupled with expert data analysis. The service features a once-weekly exclusive in-depth Integrated BioSci Alpha-Intelligence article (in the form of research, reports, or interviews), daily individual stocks consulting, and model portfolios.

Notably, we’ll increase our price soon. SUBSCRIBE to our marketplace research now to lock in the legacy price and save money in the future. To receive real-time alerts on our articles as well as blogs, be sure to check out our profile page and CLICK the orange FOLLOW button . Asides the exclusivities, this article is the truncated version of the research we published in advance to IBI subscribers. Further, you can read up on Dr. Tran’s background by following this link.

Integrated BioSci Investing: A Season Greeting From Dr. Tran BioSci

Summary

• We're what we are today due to the support of our community of expert readers, who are physicians, scientists, market leaders, fund managers, analysts, executives, and everyday investors.
• We're greatly appreciative of your stock tips, advice, wisdom, partnership, and friendship.
• We're continuing to learn and to grow. Merry Christmas and a Happy Holiday to you all.

We've grown much over the years (especially this year) as we’re blessed with a growing community of expert readers, who we view as teachers, business partners, and friends. Despite that we deliver the analytical research and consulting to you, we also learn significantly from your insight, wisdom, and suggestions in the process. Many of our followers are highly accomplished professionals, including physicians, scientists, professors, hedge fund managers, analysts, and executives, as well as other market leaders. We owe you our gratitude, especially Mr. Jacky Xiao, CEO Abelardo Fraga, Drs. Thomas Valdez and Zach Hartman, as well as many others. Much appreciation for teaching us and growing with us as partners.

Figure 1: Dr. Tran BioSci Logo. (Source: Dr. Tran BioSci of Integrated BioSci Investing).

It has been a blessing, as we've made mostly winning calls that greatly benefitted our community. Nektar Therapeutics (NASDAQ:NKTR) appreciated over 210%, Spectrum Pharmaceuticals (NASDAQ:SPPI) delivers over 170% profits, Kite Pharma (NASDAQ:KITE) procured over 82%, Exelixis (NASDAQ:EXEL) banked in over 50%, just to name a few. Our expert interviewing guests, including Biotech Beast, Decision Analytics, and Terry Chrisomalis made stellar calls that profited our readers substantially. And, we are greatly appreciative of their wisdom.

We’re also thankful for Seeking Alpha, Seeking Alpha editors, Robyn Conti, and Daniel Shvartsman for their ongoing guidance and support. In addition, we wish to send our gratitude to Richard Berger, who had advised us on how to grow our marketplace ("MP"). We recommend that you join his MP, Engineered Income Investing. The former executive is wise and has a strong track record of performance.

Figure 2: Notable BioSci Performers. (Source: Google Finance)

Of note, there are many companies we’re featuring in our MP that are highly likely to appreciate substantially in 2018 and for years to come. If you have yet to sign up with Integrate BioSci Investing, right now is a good time to do so to lock in the legacy price (as we're raising the price soon). And, we're implementing stellar developments. Much excitement to come.

On the behalf of Integrated BioSci Investing, we wish you and your family a Merry Christmas and a Happy Holiday. May this season fill you with joy.

Figure 3: Christmas Greeting. (Source: Christmas WallPaper)

Author Note: We're honored that you took the time out of your busy day to read our market intelligence. Founded by Dr. Hung Tran, MD, MS, CNPR, (in collaborations with Dr. Tran BioSci analyst, Ngoc Vu, and other PhDs), Integrated BioSci Investing marketplace research is delivering stellar returns since inceptions. To name a few, Nektar Therapeutics procured more than 210% profits while Spectrum Pharmaceuticals (SPPI) delivered over 180% gains. Our secret sauce is extreme due diligence coupled with expert data analysis. The service features a once-weekly exclusive in-depth Integrated BioSci Alpha-Intelligence article (in the form of research, reports, or interviews), daily individual stocks consulting, and model portfolios.

Notably, we'll increase prices soon. Subscribe to our Marketplace research now to lock in the legacy price and save money in the future.To receive real-time alerts on our articles as well as blogs, be sure to check out our profile page and click on the orange "Follow" button. Besides the exclusives, this article is the truncated version of the research we published in advance to IBI subscribers. Further, you can read up on Dr. Tran’s background by following this link.

Bioscience Developments - An Integrated BioSci Investing Report

To learn more how Dr. Tran BioSci can serve your specific needs ...

If you enjoy reading our research, be sure to sign up for our mailing list at Dr. Tran BioSci to get the latest market outperforming insights.

To access the complete article, please go to the premier investing research platform Seeking Alpha.

Helping The Torch Foundation - An Integrated BioSci Investing Outreach

Summary

• Torch Foundation is helping underprivileged American teens.
• You're invited to the masquerade ball fundraising event on Nov. 1st.
• Consider donating to the foundation even if you cannot participate in the said event.

Dear investors,

I'm writing on the behalf of my friend, Joe Hang, who is an activist helping underprivileged teenage American girls (age 13-17). Empowering America's youth (and donating school supplies to kids), Joe works with the organization in raising money to support their mission. The aforesaid organization is holding a masquerade ball fundraiser event (on Nov. 1). It will be held at 930 S. San Pedro, Los Angeles CA 90015. You all are invited to the event.

I already contributed my small share by donating through my marketplace research, Integrated BioSci Investing. And, I am reaching out to you to consider donating (to the purpose greater than that of ourselves), even if you cannot attend the event.

You should pass along the help to others, especially if you've benefited much from my recommendations on stellar biosciences firms (such as Spectrum Pharmaceuticals (NASDAQ:SPPI), Exelixis (NASDAQ:EXEL), Gilead Sciences (NASDAQ:GILD), Kite Pharma (NASDAQ:KITE), Alpine Immune Sciences (NASDAQ:OTC:ALPN), and Nektar Therapeutics (NASDAQ:NKTR).

Source: Dr. Tran BioSci (Adapted from Google Finance)

Together, we can build a better future for America. All your efforts count. Here is the link to their website, where you can make your donation. Thank you all for your readership and support.

Sincerely,

Dr. Tran
Chief Medical Analyst, Integrated BioSci Investing

Elucidating The Ramifications Of The Celestial Trial

To learn more how Dr. Tran BioSci can serve your specific needs ...

If you enjoy reading our research, be sure to sign up for our mailing list at Dr. Tran BioSci to get the latest market outperforming insights.

To access the complete article, please go to the premier investing research platform Seeking Alpha.

Integrated BioSci Investing: Latest Bioscience Breakthroughs

To learn more how Dr. Tran BioSci can serve your specific needs ...

If you enjoy reading our research, be sure to sign up for our mailing list at Dr. Tran BioSci to get the latest market outperforming insights.

To access the complete article, please go to the premier investing research platform Seeking Alpha.

Integrated BioSci Investing: CAR-T FDA Approved And Promising Developments

Summary

• CAR-TCR received FDA approval for the treatment of non-Hodgkin lymphoma.
• Kite, Exelixis, and Spectrum are delivering stellar returns for subscribers.
• We intend to increase the forecasting of both clinical and regulatory catalysts.
• Integrated BioSci Investing portfolio is yielding an overall robust return.

The biotech sector is highly promising with merger and acquisition to boost for stellar profits. In the past 52-weeks, Kite Pharma (NASDAQ:KITE) was acquired by Gilead Sciences Inc (NASDAQ:GILD) for $11.9B (on Aug. 28, 2017). This catapulted our portfolio’s profits on Kite to 82%. As this story is playing out, the FDA approved CAR-TCR as the treatment for non-Hodgkin lymphoma (on Oct. 18, 2017). The stellar news (for both patients and investors) gives further credence to our thesis on CAR-TCR (as a major breakthrough since the introduction of chemotherapy, half a decade prior).

Source: Google Finance

A Look At The Twin Towers Of Cancer Therapeutics

To learn more how Dr. Tran BioSci can serve your specific needs ...

If you enjoy reading our research, be sure to sign up for our mailing list at Dr. Tran BioSci to get the latest market outperforming insights.

To access the complete article, please go to the premier investing research platform Seeking Alpha.

Exelixis: Substantial Unlocked Value In The Cabozantinib Franchises

Summary

• By inhibiting multiple targets simultaneously, the anti-cancer molecule cabozantinib is showing stellar efficacy and safety in treating various cancer types.

• While procuring meaningful revenues, the development of cabozantinib for a vast number of cancer indications ensures strong future sales growth.

• Most of the clinical trials studying cabozantinib will highly likely post positive future results.

• Despite the recent run-up in share price, there are substantial values to be unlocked in the aforesaid tyrosine kinases inhibitor.

Background

As part of the biotech bull run that commenced in late 2016, Exelixis, Inc. (NASDAQ: EXEL) rewarded shareholders with more than four-folds appreciation in share price for the past year. Based in San Francisco, California, the firm is focusing on the development and commercialization of molecules to improve the outcome and care for patients afflicted by cancers. While it is seemingly the market sentiment that share price is trading at a premium, our analytical research proved otherwise. There is substantial unlocked value in the cabozantinib franchises that, in and of itself, ensures aggressive future sales growth. And despite that the company has a highly enriched pipeline, we shall evaluate the prospects of cabozantinib alone in this research.

To learn more how Dr. Tran BioSci can serve your specific needs ...

(If you enjoy reading our research, be sure to sign up for our mailing list at Dr. Tran BioSci to get the latest market outperforming insights).

To access the complete article, please go to the premier investing research platform Seeking Alpha.